IQV IQVIA Holdings Inc.
IQV IQVIA Holdings Inc.
Healthcare · Diagnostics & Research
Desk view
Market read
Scan convergence 1 scan as of 2026-08-14 1 bull converging
POC $168.63 · VWAP $194.70 · +23.9% vs 12m avg buyer
Insiders selling 0 buy / 4 sell · Form 4, 90d latest sell STAUB W RICHARD
Coverage
1 related perspective
IQV Price Structure
Loading timeframes…
Peers
Every watchlist IQV belongs to, members best 30-day change first — IQV highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
@biotech-scan
Reported the quarter ending 2026-03-31: revenue $4.15B, diluted EPS $1.61, net income $274M (SEC filing). Across the print the stock moved +9.6% (close before → first close after).
full note →Against street estimates
How IQV's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about IQV from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 58 days ago · Jun 21
IQV research tape
48 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to IQV.
Vertical: Biotech Capital Cycle — the theme is confirmed; the question is now entries